FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Vermorken

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Co-author Network

Publications

TOP 3
Jan B Vermorken; S Wind; E Ehrnrooth; A Lahogue; K Pelling; Sylvie Rottey; Jean-Pascal Machiels
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Paul Sabbatini; Giovanni Scambia; Simona Scartoni; Barbara Schmalfeldt; Jalid Sehouli; Luigi Selvaggi; Cecilia Simonelli; Jan B Vermorken; Pauline Wimberger; Tamas Pinter; Eric Pujade-Lauraine; Klaus H Baumann; Jonathan S Berek; Monica Bertolotti; Mariusz Bidzinski; Angela Capriati; Antonio Casado; David Cibula; Nicoletta Colombo; Karel Cwiertka; Jose Del Campo; Philipp Harter; Robert W Holloway; Christian Kurzeder; Andrew Li; Carlo Alberto Maggi; Andrea Martoni; Werner Meier; Jacobus Pfisterer
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO--The MIMOSA Study.
Lisa Licitra; Robert Pirker; Stephan Störkel; Eric Van Cutsem; Jan B Vermorken; Anja von Heydebreck; Ilhan Celik; Regina Esser; Fred R Hirsch; Keith M Kerr; Fortunato Ciardiello
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Vermorken (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jan B Vermorken; S Wind; E Ehrnrooth; A Lahogue; K Pelling; Sylvie Rottey; Jean-Pascal Machiels
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(5):1392-400.
2013: Paul Sabbatini; Giovanni Scambia; Simona Scartoni; Barbara Schmalfeldt; Jalid Sehouli; Luigi Selvaggi; Cecilia Simonelli; Jan B Vermorken; Pauline Wimberger; Tamas Pinter; Eric Pujade-Lauraine; Klaus H Baumann; Jonathan S Berek; Monica Bertolotti; Mariusz Bidzinski; Angela Capriati; Antonio Casado; David Cibula; Nicoletta Colombo; Karel Cwiertka; Jose Del Campo; Philipp Harter; Robert W Holloway; Christian Kurzeder; Andrew Li; Carlo Alberto Maggi; Andrea Martoni; Werner Meier; Jacobus Pfisterer
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO--The MIMOSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(12):1554-61.
2013: Lisa Licitra; Robert Pirker; Stephan Störkel; Eric Van Cutsem; Jan B Vermorken; Anja von Heydebreck; Ilhan Celik; Regina Esser; Fred R Hirsch; Keith M Kerr; Fortunato Ciardiello
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
European journal of cancer (Oxford, England : 1990) 2013;49(6):1161-8.
2013: José María del Campo; Javier Gómez; Martin Gore; Stan Kaye; Carolyn N Krasner; Trilok Parekh; Youn Choi Park; Cristiana Sessa; Jan B Vermorken; Patrik Zintl; Nicoletta Colombo; Scott McMeekin
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
Medical oncology (Northwood, London, England) 2013;30(1):435.
2013: Dirk Van Gestel; Corine van Vliet-Vroegindeweij; Jan B Vermorken; Ann Coelmont; Wouter Crijns; Bie De Ost; Yasmyne Geussens; Andrea Holt; Emmy Lamers; Sandra Nuyts; Frank Van den Heuvel; Danielle Van den Weyngaert; Tim Van den Wyngaert; Vincent Gregoire
RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison.
Radiation oncology (London, England) 2013;8():37.
2013: An Wouters; Carolien Boeckx; Marc Peeters; Danielle Van den Weyngaert; Jan B Vermorken; Filip Lardon
The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors.
Current pharmaceutical design 2013;19(5):907-17.
2012: Yassine Lalami; J A Langendijk; Cecilia Liberatoscioli; Pol M Specenier; Guy Andry; Ahmad Awada; Jan Bogaerts; Iman El-Hariry; Catherine Fortpied; Denis Lacombe; Jan B Vermorken
EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012;105(2):238-40.
2012: Carolyn N Krasner; Pilar Lardelli Claret; Thomas J Herzog; Stanley B Kaye; Antonio Nieto; Trilok Parekh; Youn Choi Park; Andres Poveda; Jan B Vermorken; Bradley J Monk
Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone.
Gynecologic oncology 2012;127(1):161-7.
2012: Bradley J Monk; Franco M Muggia; Trilok V Parekh; Youn C Park; Thomas J Herzog; Stanley B Kaye; Carolyn N Krasner; Eric Pujade-Lauraine; Jan B Vermorken; Andres M Poveda
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
European journal of cancer (Oxford, England : 1990) 2012;48(15):2361-8.
2012: Eric Van Cutsem; Dirk Vanbeckevoort; Jan B Vermorken; Frederic Viret; Soetkin Vlassak; Annemieke Cats; Elisa Gallerani; Hans Gelderblom; Bengt Glimelius; Alain Hendlisz; Yves Humblet; Markus Moehler; Marc Peeters; Xavier Sagaert; Michael Schlichting; Sabine Tejpar; Fortunato Ciardiello
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(23):2861-8.
2012: Vincent A de Weger; Zelda Euler; Elisabeth Bloemena; Herman Bril; Gerrit A Meijer; HERBERT PINEDO; Annelies W Turksma; Alfons J van den Eertwegh; Harm van Tinteren; Jan B Vermorken; Quirinus J M Voorham; Erik Hooijberg
Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(3):882-9.
2012: Pol Specenier; Jan B Vermorken
Biologic therapy in head and neck cancer: a road with hurdles.
ISRN oncology 2012;2012():163752.
2011: Carolien Boeckx; Vanessa Deschoolmeester; Filip Lardon; Krzysztof Lukaszuk; Bea Pauwels; Patrick Pauwels; Marc Peeters; Pol Specenier; Jan B Vermorken; An Wouters; Marc F D Baay
Expression analysis on archival material: comparison of 5 commercially available RNA isolation kits for FFPE material.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011;20(4):203-11.
2011: Tim Van den Wyngaert; Manon T Huizing; Kristien Wouters; Jan B Vermorken
RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2011;19(12):2035-40.
2011: Pol Specenier; Jan Van den Brande; Philippe Vroman; Joke Dyck; Manon T Huizing; Marika Rasschaert; Dirk Schrijvers; Jan B Vermorken
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
American journal of clinical oncology 2011;34(5):472-7.
2011: Thomas J Herzog; Agnieszka Jagiello-Gruszfeld; Beihua Kong; Claudia Lebedinsky; Trilok Parekh; Youn Choi Park; Diane M Provencher; Eric Pujade-Lauraine; Jan B Vermorken; Karin Boman; Javier Gómez; Bradley J Monk
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Gynecologic oncology 2011;122(2):350-5.
2011: P Specenier; Danielle Van den Weyngaert; Joost Weyler; K Aelbrecht; G De Boeck; Joke Dyck; Gunther Guetens; Jan B Vermorken
Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients.
Cancer chemotherapy and pharmacology 2011;68(1):185-91.
2011: An Wouters; Bea Pauwels; Hilde A J Lambrechts; Greet G O Pattyn; Johan Ides; Marc Baay; Paul Meijnders; Marc Peeters; Jan B Vermorken; Filip Lardon
Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.
International journal of radiation oncology, biology, physics 2011;80(2):558-66.
2011: Jan B Vermorken; J Guigay; R Mesia; José M Trigo; U Keilholz; A Kerber; U Bethe; M Picard; T H Brummendorf
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
British journal of cancer 2011;104(11):1691-6.
2011: Monica Bacon; Henry Kitchener; Gavin C E Stuart; Jan B Vermorken
The global impact of the Gynecologic Cancer InterGroup in enhancing clinical trials in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011;21(4):746-9.
2011: Pol Specenier; Jan B Vermorken
Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Expert review of anticancer therapy 2011;11(4):511-24.
2011: D Van Gestel; D Van Den Weyngaert; Dirk Schrijvers; Joost Weyler; Jan B Vermorken
Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience.
The British journal of radiology 2011;84(1000):367-74.
2011: Marc F D Baay; Katrien Francois; Filip Lardon; Paul Van Royen; Patrick Pauwels; Jan B Vermorken; Marc Peeters; Veronique Verhoeven
The presence of Y chromosomal deoxyribonucleic acid in the female vaginal swab: possible implications for human papillomavirus testing.
Cancer epidemiology 2011;35(1):101-3.
2011: Tim Van den Wyngaert; manon huizing; Eric Fossion; Jan B Vermorken
Prognostic value of bone scintigraphy in cancer patients with osteonecrosis of the jaw.
Clinical nuclear medicine 2011;36(1):17-20.
2010: V Deschoolmeester; C Boeckx; Marc Baay; Joost Weyler; W Wuyts; Eric Van Marck; M Peeters; Filip Lardon; Jan B Vermorken
KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis.
British journal of cancer 2010;103(10):1627-36.
2010: Jan B Vermorken; P Specenier
Optimal treatment for recurrent/metastatic head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 7():vii252-61.
2010: Veronique Verhoeven; Marc Baay; Pieter E Baay; Filip Lardon; Paul Van Royen; Jan B Vermorken
Everything you always wanted to know about HPV (but could not ask your doctor).
Patient education and counseling 2010;81(1):101-5.
2010: Bea Pauwels; An Wouters; Marc Peeters; Jan B Vermorken; Filip Lardon
Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.
Future oncology (London, England) 2010;6(9):1485-96.
2010: Jean Bourhis; Jean-Louis Lefebvre; Jan B Vermorken
Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
European journal of cancer (Oxford, England : 1990) 2010;46(11):1979-89.
2010: Bradley J Monk; Thomas J Herzog; Stanley B Kaye; Carolyn N Krasner; Jan B Vermorken; Franco M Muggia; Eric Pujade-Lauraine; Alla S Lisyanskaya; Anatoly N Makhson; Janusz Rolski; Vera A Gorbounova; Prafull Ghatage; Mariusz Bidzinski; Keng Shen; Hextan Yuen-Sheung Ngan; Ignace B Vergote; Joo-Hyun Nam; Youn Choi Park; Claudia A Lebedinsky; Andrés M Poveda
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3107-14.
2010: Pol Specenier; Jan B Vermorken
Advances in the systemic treatment of head and neck cancers.
Current opinion in oncology 2010;22(3):200-5.
2010: An Wouters; Bea Pauwels; Hilde A J Lambrechts; Greet G O Pattyn; Johan Ides; Marc Baay; Paul Meijnders; Filip Lardon; Jan B Vermorken
Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software.
Physics in medicine and biology 2010;55(7):N167-78.
2010: Tim Van den Wyngaert; manon huizing; Eric Fossion; Jan B Vermorken
Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.
Oral oncology 2010;46(3):214-8.
2010: Pol Specenier; Marika Rasschaert; Jan Van den Brande; Joke Dyck; Dirk Schrijvers; manon huizing; Jan B Vermorken
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Anti-cancer drugs 2010;21(3):306-12.
2010: Jan B Vermorken
A new look at induction chemotherapy in locally advanced head and neck cancer.
The oncologist 2010;15 Suppl 3():1-2.
2010: An Wouters; Bea Pauwels; Filip Lardon; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Paul Meijnders; Jan B Vermorken
In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
BMC cancer 2010;10():441.
2010: Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
The oncologist 2010;15(7):699-731.
2010: Eyrun F Kjetland; Patricia D Ndhlovu; Takafira MDULUZA; V Deschoolmeester; Nicholas Midzi; Exnevia Gomo; Lovemore Gwanzura; Peter R Mason; Jan B Vermorken; Henrik Friis; Svein Gunnar Gundersen; Marc Baay
The effects of genital schistosoma haematobium on human papillomavirus and the development of cervical neoplasia after five years in a Zimbabwean population.
European journal of gynaecological oncology 2010;31(2):169-73.
2010: Vanessa Deschoolmeester; Marc Baay; Eric Van Marck; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken
Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.
BMC immunology 2010;11():19.
2010: Vanessa Deschoolmeester; Veerle Van Marck; Marc Baay; Christine Weyn; Peter Vermeulen; Eric Van Marck; Filip Lardon; Veronique Fontaine; Jan B Vermorken
Detection of HPV and the role of p16INK4A overexpression as a surrogate marker for the presence of functional HPV oncoprotein E7 in colorectal cancer.
BMC cancer 2010;10():117.
2009: An Wouters; Bea Pauwels; Hilde A J Lambrechts; Greet G O Pattyn; Johan Ides; Marc Baay; Paul Meijnders; Sylvia Dewilde; Jan B Vermorken; Filip Lardon
Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model.
Cancer letters 2009;286(2):180-8.
2009: Pol M Specenier; Jan Van den Brande; Dirk Schrijvers; manon huizing; Sevilay Altintas; Joke Dyck; Danielle Van den Weyngaert; Carl Van Laer; Jan B Vermorken
Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.
Anticancer research 2009;29(12):5137-42.
2009: Andrés Poveda; Jan B Vermorken
The International Symposium on Advanced Ovarian Cancer. February 27, 2009, Spain.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19 Suppl 2():S1.
2009: Bea Pauwels; Jan B Vermorken; A Wouters; J Ides; S Van Laere; Hilde A J Lambrechts; Greet G O Pattyn; Katrien Vermeulen; P Meijnders; Filip Lardon
The role of apoptotic cell death in the radiosensitising effect of gemcitabine.
British journal of cancer 2009;101(4):628-36.
2009: Jan B Vermorken
Annals of oncology: some modest proposals but some great aims.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1289-90.
2009: Pol M Specenier; tudor ciuleanu; Jane E Latz; Luna C Musib; Christelle L S Darstein; Jan B Vermorken
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.
Cancer chemotherapy and pharmacology 2009;64(2):233-41.
2009: Jacques Bernier; Søren M Bentzen; Jan B Vermorken
Molecular therapy in head and neck oncology.
Nature reviews. Clinical oncology 2009;6(5):266-77.
2009: Stefan Michiels; Aurélie Le Maître; Marc Buyse; Tomasz Burzykowski; Emilie Maillard; Jan Bogaerts; Jan B Vermorken; Wilfried Budach; Thomas F Pajak; Kian K Ang; Jean Bourhis; Jean-Pierre Pignon
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
The lancet oncology 2009;10(4):341-50.
2009: Pol M Specenier; Jan B Vermorken
Current concepts for the management of head and neck cancer: chemotherapy.
Oral oncology 2009;45(4-5):409-15.
2009: Sevilay Altintas; Kathleen Lambein; manon huizing; Geert Braems; Fernando Tjin Asjoe; Hilde Hellemans; Eric Van Marck; Joost Weyler; Marleen Praet; Rudy Van den Broecke; Jan B Vermorken; Wiebren A Tjalma
Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
The breast journal 2009;15(2):120-32.
2009: Tim Van den Wyngaert; manon huizing; Eric Fossion; Jan B Vermorken
Bisphosphonates in oncology: rising stars or fallen heroes.
The oncologist 2009;14(2):181-91.
2009: Tim Van den Wyngaert; T Claeys; manon huizing; Jan B Vermorken; E Fossion
Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(2):331-6.
2009: Pol M Specenier; Joost Weyler; Carl Van Laer; Danielle Van den Weyngaert; Jan Van den Brande; manon huizing; Sevilay Altintas; Jan B Vermorken
A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
BMC cancer 2009;9():273.
2009: Marc Baay; M Nakonieczny; I Wozniak; V Deschoolmeester; J Liss; K Lukaszuk; K Sotlar; J Emerich; Jan B Vermorken
Microsatellite instability and HPV genotype in Polish women with cervical cancer.
European journal of gynaecological oncology 2009;30(2):162-6.
2008: Vanessa Deschoolmeester; Nancy Van Damme; Marc Baay; Kathleen Claes; Eric Van Marck; Filip J Baert; Wim Wuyts; Marc Cabooter; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken; Marc Peeters
Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population.
European journal of cancer (Oxford, England : 1990) 2008;44(15):2288-95.
2008: Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
The New England journal of medicine 2008;359(11):1116-27.
2008: Alexander D Rapidis; Jan B Vermorken; Jean Bourhis
Targeted therapies in head and neck cancer: past, present and future.
Reviews on recent clinical trials 2008;3(3):156-66.
2008: Cindy Simoens; Bea Pauwels; Jan B Vermorken; Greet G O Pattyn; Hilde A J Lambrechts; Fabienne Breillout; Filip Lardon
Further mechanistic unravelling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro.
Cancer chemotherapy and pharmacology 2008;62(2):183-93.
2008: Jan B Vermorken; Roy S Herbst; Xavier Leon; Nadia Amellal; Jose Baselga
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Cancer 2008;112(12):2710-9.
2008: Marshall R Posner; Jan B Vermorken
Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer.
Seminars in oncology 2008;35(3):221-8.
2008: Jan P A Baak; Paulus van Diest; Emiel Janssen; einar gudlaugsson; Feja J Voorhorst; ELSKEN VAN DER WALL; Jan B Vermorken
Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(4):649-54.
2008: Pol M Specenier; Jan B Vermorken
Recurrent head and neck cancer: current treatment and future prospects.
Expert review of anticancer therapy 2008;8(3):375-91.
2008: Jan B Vermorken
Second-line randomized trials in epithelial ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():59-66.
2008: Vanessa Deschoolmeester; Marc Baay; Wim Wuyts; Eric Van Marck; Nancy Van Damme; Peter Vermeulen; Krzysztof Lukaszuk; Filip Lardon; Jan B Vermorken
Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers.
The Journal of molecular diagnostics : JMD 2008;10(2):154-9.
2008: Cindy Simoens; Filip Lardon; Bea Pauwels; Christel M J de Pooter; Hilde A J Lambrechts; Greet G O Pattyn; Fabienne Breillout; Jan B Vermorken
Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro.
BMC cancer 2008;8():65.
2007: Marco J J H Grootenboers; Jeroen Hendriks; Wim-Jan van Boven; Catherijne A J Knibbe; Bart P Van Putte; Bernard Stockman; Ernst A de Bruijn; Jan B Vermorken; Paul E Y Van Schil; Franz Schramel
Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Journal of surgical oncology 2007;96(7):583-9.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nicholas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Hilary Calvert; Alan V Boddy; Harry Hollema; Regine Féty; Wjf J F Van der Vijgh; Georg Hempel; Etienne Chatelut; Mats Karlsson; Justin Wilkins; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Markus Joerger; Alwin D R Huitema; manon huizing; P H B Willemse; A de Graeff; Hilde Rosing; J H M Schellens; Jos H Beijnen; Jan B Vermorken
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: P M Specenier; Danielle Van den Weyngaert; C Van Laer; J Weyler; Jan Van den Brande; manon huizing; Joke Dyck; Dirk Schrijvers; Jan B Vermorken
Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(11):1856-60.
2007: Pol M Specenier; Jan B Vermorken
Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
Cancer letters 2007;256(2):166-77.
2007: Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle Van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
The New England journal of medicine 2007;357(17):1695-704.
2007: Fernando Tjin Asjoe; Sevilay Altintas; manon huizing; Cecile Colpaert; Erik Van Marck; Jan B Vermorken; W A A Tjalma
The value of the Van Nuys Prognostic Index in ductal carcinoma in situ of the breast: a retrospective analysis.
The breast journal 2007;13(4):359-67.
2007: Tim Van den Wyngaert; manon huizing; Jan B Vermorken
Osteonecrosis of the jaw related to the use of bisphosphonates.
Current opinion in oncology 2007;19(4):315-22.
2007: M Rasschaert; Dirk Schrijvers; Jan Van den Brande; Joke Dyck; J Bosmans; K Merkle; Jan B Vermorken
A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
British journal of cancer 2007;96(11):1692-8.
2007: An Wouters; Bea Pauwels; Filip Lardon; Jan B Vermorken
Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions.
The oncologist 2007;12(6):690-712.
2007: Jan B Vermorken; José M Trigo; Ricardo Hitt; Piotr Koralewski; Eduardo Diaz-Rubio; Frédéric Rolland; Rainald Knecht; Nadia Amellal; Armin Schueler; José Baselga
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2171-7.
2007: Marika Rasschaert; Dirk Schrijvers; Jan Van den Brande; Joke Dyck; Johan Bosmans; Karlheinz Merkle; Jan B Vermorken
A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Anti-cancer drugs 2007;18(5):587-95.
2007: Pol Specenier; Jan B Vermorken
The role of taxanes and targeted therapies in locally advanced head and neck cancer.
Current opinion in oncology 2007;19(3):195-201.
2007: Godefridus J Peters; MD Clavel; Paul Noordhuis; G J Geyssen; Adrie C Laan; Jean-Paul Guastalla; H T Edzes; Jan B Vermorken
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Journal of chemotherapy (Florence, Italy) 2007;19(2):212-21.
2007: S Altintas; N Blockx; manon huizing; Jan Van den Brande; L Hoekx; J P Bogers; E Van Marck; Jan B Vermorken
Small-cell carcinoma of the penile urethra: a case report and a short review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):801-4.
2007: Jan P A Baak; Paulus van Diest; Feja J Voorhorst; ELSKEN VAN DER WALL; Louk V A M Beex; Jan B Vermorken; Emiel Janssen; einar gudlaugsson
The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.
European journal of cancer (Oxford, England : 1990) 2007;43(3):527-35.
2007: I F van Luijk; Corneel Coens; M E L van der Burg; A Kobierska; M Namer; C Lhomme; Paolo Zola; Gerardo Zanetta; Jan B Vermorken
Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):275-81.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2006: Veronique Verhoeven; Marc Baay; Annelies Colliers; Ann Verster; Paul Van Royen; Dirk Avonts; Jan B Vermorken
The male factor in cervical carcinogenesis: a questionnaire study of men's awareness in primary care.
Preventive medicine 2006;43(5):389-93.
2006: Jan B Vermorken
Intraperitoneal chemotherapy in advanced ovarian cancer: recognition at last.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x241-6.
2006: Tim Van den Wyngaert; manon huizing; Jan B Vermorken
Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1197-204.
2006: Bea Pauwels; Annelies E C Korst; Hilde A J Lambrechts; Greet G O Pattyn; Christel M J de Pooter; Filip Lardon; Jan B Vermorken
The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro.
Cancer chemotherapy and pharmacology 2006;58(2):219-28.
2006: Cindy Simoens; Jan B Vermorken; Annelies E C Korst; Bea Pauwels; Christel M J de Pooter; Greet G O Pattyn; Hilde A J Lambrechts; Fabienne Breillout; Filip Lardon
Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro.
Cancer chemotherapy and pharmacology 2006;58(2):210-8.
2006: Jacques Bernier; Jan B Vermorken; Wayne M Koch
Adjuvant therapy in patients with resected poor-risk head and neck cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(17):2629-35.
2006: Emiel Janssen; Paulus van Diest; Håvard Søiland; einar gudlaugsson; Arne Nysted; Feja J Voorhorst; Jan B Vermorken; Jon Arne Søreide; Jan P A Baak
Success predictors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2006;28(5-6):295-303.
2006: Bea Pauwels; Annelies E C Korst; Greet G O Pattyn; Hilde A J Lambrechts; Juliette A E Kamphuis; Christel M J de Pooter; Godefridus J Peters; Filip Lardon; Jan B Vermorken
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
BMC cancer 2006;6():142.
2006: Vanessa Deschoolmeester; Marc Baay; Wim Wuyts; Eric Van Marck; Paul A Pelckmans; Filip Lardon; Jan B Vermorken
Comparison of three commonly used PCR-based techniques to analyze MSI status in sporadic colorectal cancer.
Journal of clinical laboratory analysis 2006;20(2):52-61.
2005: Dirk Schrijvers; Jan B Vermorken
Taxanes in head and neck cancer.
Future oncology (London, England) 2005;1(6):829-39.
2005: Marc Baay; W A A Tjalma; Hilde A J Lambrechts; Greet G O Pattyn; Filip Lardon; Joost Weyler; Paul Van Royen; Eric A Van Marck; Jan B Vermorken
Combined Pap and HPV testing in primary screening for cervical abnormalities: should HPV detection be delayed until age 35?
European journal of cancer (Oxford, England : 1990) 2005;41(17):2704-8.
2005: Bea Pauwels; Annelies E C Korst; Veronique Andriessen; Marc Baay; Greet G O Pattyn; Hilde A J Lambrechts; Christel M J De Pooter; Filip Lardon; Jan B Vermorken
Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53.
Radiation research 2005;164(5):642-50.
2005: Jan P A Baak; Paulus van Diest; Feja J Voorhorst; ELSKEN VAN DER WALL; Louk V A M Beex; Jan B Vermorken; Emiel Janssen
Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5993-6001.
2005: Bart P Van Putte; Jeroen Hendriks; Sander Romijn; Bea Pauwels; Jan B Vermorken; Paul E Y Van Schil
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
The Journal of thoracic and cardiovascular surgery 2005;130(1):125-30.
2005: Dirk Schrijvers; Jan B Vermorken
Taxanes in the treatment of head and neck cancer.
Current opinion in oncology 2005;17(3):218-24.
2005: M Quinn; E Avall-Lundqvist; Andreas du Bois; Jan B Vermorken; Mahesh Parmar; Jacobus Pfisterer; G Stuart; Tate Thigpen; JP Neijt
History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii5-viii6.
2005: Jan B Vermorken; E Avall-Lundqvist; Jacobus Pfisterer; M Bacon
The Gynecologic Cancer Intergroup (GCIG): history and current status.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 8():viii39-viii42.
2005: Jan B Vermorken
Medical treatment in head and neck cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16 Suppl 2():ii258-64.
2005: Bea Pauwels; Annelies E C Korst; Filip Lardon; Jan B Vermorken
Combined modality therapy of gemcitabine and radiation.
The oncologist 2005;10(1):34-51.
2004: Florence Duffaud; Markus M Borner; P Chollet; Jan B Vermorken; J Bloch; Marian Degardin; Frédéric Rolland; Christian Dittrich; B Baron; Denis Lacombe; Pierre Fumoleau
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
European journal of cancer (Oxford, England : 1990) 2004;40(18):2748-52.
2004: Jeroen Hendriks; Marco J J H Grootenboers; Franz Schramel; Wim-Jan van Boven; Bernard Stockman; Cornelis A Seldenrijk; Pieter W ten Broecke; Catherijne A J Knibbe; Peter Slee; Ernst A de Bruijn; Renate Vlaeminck; Jos Heeren; Jan B Vermorken; Bart P Van Putte; Sander Romijn; Eric Van Marck; Paul E Y Van Schil
Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial.
The Annals of thoracic surgery 2004;78(6):1919-26; discussion 1926-7.
2004: Veronique Verhoeven; Marc Baay; Joost Weyler; Dirk Avonts; Filip Lardon; Paul Van Royen; Jan B Vermorken
Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2004;23(9):735-7.
2004: Marc Baay; Eyrun F Kjetland; Patricia D Ndhlovu; Vanessa Deschoolmeester; Takafira MDULUZA; Exnevia Gomo; Henrik Friis; Nicholas Midzi; Lovemore Gwanzura; Peter R Mason; Jan B Vermorken; Svein Gunnar Gundersen
Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution.
Journal of medical virology 2004;73(3):481-5.
2004: Dirk Schrijvers; C Van Herpen; J Kerger; E Joosens; C Van Laer; A Awada; Danielle Van den Weyngaert; H Nguyen; C Le Bouder; J A Castelijns; J Kaanders; P De Mulder; Jan B Vermorken
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(4):638-45.
2004: Marc Baay; Evelien Smits; W A A Tjalma; Filip Lardon; Joost Weyler; Paul Van Royen; Eric A Van Marck; Jan B Vermorken
Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women.
International journal of cancer. Journal international du cancer 2004;108(2):258-61.
2004: Marc Baay; Veronique Verhoeven; Dirk Avonts; Jan B Vermorken
Risk factors for cervical cancer development: what do women think?
Sexual health 2004;1(3):145-9.
2004: Marc Baay; Joost Weyler; Jan B Vermorken
The value of human papillomavirus detection in primary cervical cancer screening.
European journal of gynaecological oncology 2004;25(6):665-9.
2004: Marc Baay; Veronique Verhoeven; Kristien Wouters; Filip Lardon; Pierre Van Damme; Dirk Avonts; Eric Van Marck; Paul Van Royen; Jan B Vermorken
The prevalence of the human papillomavirus in cervix and vagina in low-risk and high-risk populations.
Scandinavian journal of infectious diseases 2004;36(6-7):456-9.
2004: J Mebis; H De Raeve; M Baekelandt; W A A Tjalma; Jan B Vermorken
Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature.
European journal of gynaecological oncology 2004;25(2):239-41.
2004: Sandro Pignata; Jan B Vermorken
Ovarian cancer in the elderly.
Critical reviews in oncology/hematology 2004;49(1):77-86.
2003: C Simoens; Annelies E C Korst; Christel M J de Pooter; Hilde A J Lambrechts; Greet G O Pattyn; G T Faircloth; Filip Lardon; Jan B Vermorken
In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
British journal of cancer 2003;89(12):2305-11.
2003: Bea Pauwels; Annelies E C Korst; Greet G O Pattyn; Hilde A J Lambrechts; Dirk R Van Bockstaele; Katrien Vermeulen; Marc Lenjou; Christel M J de Pooter; Jan B Vermorken; Filip Lardon
Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro.
International journal of radiation oncology, biology, physics 2003;57(4):1075-83.
2003: M J Piccart; A Floquet; Giovanna Scarfone; P H B Willemse; J Emerich; Ignace Vergote; L Giurgea; Corneel Coens; A Awada; Jan B Vermorken
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():196-203.
2003: Jan B Vermorken
The role of anthracyclines in second-line therapy of ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():178-84.
2003: Chris Twelves; K Hoekman; Adrian Bowman; Jan B Vermorken; Alan Anthoney; J Smyth; Charlotte van Kesteren; Jos H Beijnen; J Uiters; Jantien Wanders; J Gomez; C Guzmán; José Jimeno; Axel R Hanauske
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1842-51.
2003: M S Aapro; F H van Wijk; M E L van der Burg; W ten Bokkel Huinink; Ignace Vergote; J P Guastalla; R Rosso; A Kobierska; L V A Beex; M Namer; T E W Splinter; Jan B Vermorken
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1141-3.
2003: Bea Pauwels; Annelies E C Korst; Christel M J de Pooter; Hilde A J Lambrechts; Greet G O Pattyn; Filip Lardon; Jan B Vermorken
The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro.
European journal of cancer (Oxford, England : 1990) 2003;39(6):838-46.
2003: Jan Van den Brande; Patrick Schöffski; J H M Schellens; A D Roth; F Duffaud; K Weigang-Köhler; F Reinke; Jantien Wanders; R F de Boer; Jan B Vermorken; Pierre Fumoleau
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
British journal of cancer 2003;88(5):648-53.
2003: R E N van Rijswijk; Jan B Vermorken; N Reed; Giuseppe Favalli; C Mendiola; FLAVIA ZANABONI; giorgia mangili; Ignace Vergote; J P Guastalla; W W ten Bokkel Huinink; AJ Lacave; Hervé Bonnefoi; S Tumulo; R Rietbroek; I Teodorovic; Corneel Coens; Sergio Pecorelli
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
European journal of cancer (Oxford, England : 1990) 2003;39(4):481-7.
2003: Bea Pauwels; Annelies E C Korst; Christel M J de Pooter; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Filip Lardon; Jan B Vermorken
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies.
Cancer chemotherapy and pharmacology 2003;51(3):221-6.
2003: Jan B Vermorken; V F I Van Tendeloo
Dendritic cell therapy of cancer: can it fulfill its promise?
Expert review of anticancer therapy 2003;3(1):1-3.
2003: Jeroen Hendriks; Bart P Van Putte; Sander Romijn; J van den Brande; Jan B Vermorken; Paul E Y Van Schil
Pneumonectomy for lung metastases: report of ten cases.
The Thoracic and cardiovascular surgeon 2003;51(1):38-41.
2003: J Baptist Trimbos; Ignace Vergote; Giorgio Bolis; Jan B Vermorken; Costantino Mangioni; Caterina Madronal; Massimo Franchi; Saverio Tateo; Gerardo Zanetta; Giovanna Scarfone; Livia Giurgea; Petra Timmers; Corneel Coens; Sergio Pecorelli
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Journal of the National Cancer Institute 2003;95(2):113-25.
2003: J Baptist Trimbos; Mahesh Parmar; Ignace Vergote; David Guthrie; Giorgio Bolis; Nicoletta Colombo; Jan B Vermorken; Valter Torri; Costantino Mangioni; Sergio Pecorelli; Andrea Lissoni; Ann Marie Swart
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Journal of the National Cancer Institute 2003;95(2):105-12.
2003: F H van Wijk; C Lhommé; Giorgio Bolis; V Scotto di Palumbo; Salvatore Tumolo; Marianne A Nooij; CF de Oliveira; Jan B Vermorken
Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
European journal of cancer (Oxford, England : 1990) 2003;39(1):78-85.
2002: Dirk Schrijvers; Jan B Vermorken
Phase I studies with bendamustine: an update.
Seminars in oncology 2002;29(4 Suppl 13):15-8.
2002: Steven M Van Outryve; Dirk Schrijvers; Jan Van den Brande; P Wilmes; J Bogers; Eric Van Marck; Jan B Vermorken
Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review.
The Netherlands journal of medicine 2002;60(5):216-22.
2002: Arnold Baars; A M E Claessen; John Wagstaff; Giuseppe Giaccone; Rik J Scheper; Sybren Meijer; M J A G Schakel; Helen Gall; C J L M Meijer; Jan B Vermorken; HERBERT PINEDO; Alfons J M van den Eertwegh
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
British journal of cancer 2002;86(8):1230-4.
2002: Charlotte van Kesteren; Chris Twelves; Adrian Bowman; Klaas Hoekman; Luis López-Lázaro; José Jimeno; Cecilia Guzman; Ron A A Mathôt; Andrew Simpson; Jan B Vermorken; John Smyth; Jan H M Schellens; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Anti-cancer drugs 2002;13(4):381-93.
2002: Patrick Schöffski; A Herr; Jan B Vermorken; Jan Van den Brande; J H Beijnen; H Rosing; Joachim Volk; Arnold Ganser; S Adank; H J Botma; Jantien Wanders
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
European journal of cancer (Oxford, England : 1990) 2002;38(6):807-13.
2002: Dirk Schrijvers; A M E Bos; Joke Dyck; E G E de Vries; Jantien Wanders; MW Roelvink; Pierre Fumoleau; S Bortini; Jan B Vermorken
Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):385-91.
2002: Rob Michalides; Harm van Tinteren; Astrid Balkenende; Jan B Vermorken; J Benraadt; J Huldij; Paulus van Diest
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.
British journal of cancer 2002;86(3):402-8.
2001: Jeroen Hendriks; Sander Romijn; Bart P Van Putte; EJ Eyskens; Jan B Vermorken; Eric Van Marck; Paul E Y Van Schil
Long-term results of surgical resection of lung metastases.
Acta chirurgica Belgica 2001;101(6):267-72.
2001: A M E Bos; Elisabeth G E de Vries; P Dombernovsky; Steinar Aamdal; D R A Uges; Dirk Schrijvers; Jantien Wanders; MW Roelvink; Axel R Hanauske; S Bortini; A Capriati; AE Crea; Jan B Vermorken
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Cancer chemotherapy and pharmacology 2001;48(5):361-9.
2001: HC Wagenaar; Sergio Pecorelli; Costantino Mangioni; M E L van der Burg; N Rotmensz; A Anastasopoulou; Paolo Zola; C H Veenhof; AJ Lacave; J P Neijt; A T van Oosterom; N Einhorn; Jan B Vermorken
Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1624-8.
2001: Jan Van den Brande; VR Nannan Panday; Klaas Hoekman; H Rosing; R V Huijskes; R H Verheijen; Jos H Beijnen; Jan B Vermorken
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
American journal of clinical oncology 2001;24(4):401-3.
2001: W A A Tjalma; Joost Weyler; Johannes J P M Bogers; C Pollefliet; Marc Baay; GC Goovaerts; Jan B Vermorken; Peter van Dam; Eric A Van Marck; Philippe Buytaert
The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer.
European journal of obstetrics, gynecology, and reproductive biology 2001;97(2):223-30.
2001: Jan B Vermorken; Gerardo Zanetta; CF de Oliveira; M E L van der Burg; AJ Lacave; I Teodorovic; G H Boes; Nicoletta Colombo
Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(7):967-74.
2001: HC Wagenaar; Nicoletta Colombo; Ignace Vergote; G Hoctin-Boes; Gerardo Zanetta; Sergio Pecorelli; AJ Lacave; Q G C M van Hoesel; A Cervantes; Giorgio Bolis; M Namer; C Lhommé; J P Guastalla; Marianne A Nooij; Andres Poveda; V Scotto di Palumbo; Jan B Vermorken
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer.
Gynecologic oncology 2001;81(3):348-54.
2001: Florence Duffaud; M E L van der Burg; M Namer; Ignace Vergote; W ten Bokkel Huinink; J P Guastalla; Pierre Kerbrat; M Piccart; Salvatore Tumolo; Giuseppe Favalli; N van der Vange; AJ Lacave; Jacques A Wils; Ted A W Splinter; N Einhorn; K J Roozendaal; R Rosso; Jan B Vermorken
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
Anti-cancer drugs 2001;12(2):159-62.
2001: Marc Baay; W A A Tjalma; Joost Weyler; Greet G O Pattyn; Hilde A J Lambrechts; GC Goovaerts; M Baekelandt; Philippe Buytaert; Eric A Van Marck; Filip Lardon; Jan B Vermorken
Prevalence of human papillomavirus in elderly women with cervical cancer.
Gynecologic and obstetric investigation 2001;52(4):248-51.
2001: Marc Baay; W A A Tjalma; Joost Weyler; GC Goovaerts; Philippe Buytaert; Eric A Van Marck; Filip Lardon; Jan B Vermorken
Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer.
European journal of gynaecological oncology 2001;22(3):204-8.
2001: HC Wagenaar; Sergio Pecorelli; Ignace Vergote; Desmond Curran; D J Wagener; A Kobierska; Giorgio Bolis; W T Bokkel-Huinink; AJ Lacave; C Madronal; M Forn; CF de Oliveira; Costantino Mangioni; Marianne A Nooij; A Goupil; P Kerbrat; C H Marth; Salvatore Tumolo; M G Herben; FLAVIA ZANABONI; Jan B Vermorken
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
European journal of gynaecological oncology 2001;22(3):187-93.
2001: Jan B Vermorken
Intergroup collaboration in ovarian cancer: the Gynecologic Cancer Intergroup (GCIG).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11 Suppl 1():73-6.
2001: Jan B Vermorken
The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2001;11 Suppl 1():21-30.
2000: Jan B Vermorken
Adjuvant immunotherapy in colorectal cancer.
Seminars in oncology 2000;27(5 Suppl 10):66-71.
2000: Jan B Vermorken; A Kobierska; B Chevallier; FLAVIA ZANABONI; A Pawinski; Giorgio Bolis
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):1035-40.
2000: Arnold Baars; A M E Claessen; Alfons J M van den Eertwegh; Helen Gall; Anita G M Stam; Sybren Meijer; Giuseppe Giaccone; Chris J L M Meijer; Rik J Scheper; John Wagstaff; Jan B Vermorken; HERBERT PINEDO
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):965-70.
2000: R E N van Rijswijk; Jan B Vermorken
Drug therapy for gynaecological cancer in older women.
Drugs & aging 2000;17(1):13-32.
2000: Tjeerd J Postma; Jan J Heimans; S A Luykx; Cees J van Groeningen; LF Beenen; O S Hoekstra; Martin J B Taphoorn; BA Zonnenberg; Martin Klein; Jan B Vermorken
A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(4):409-13.
2000: Y Mentens; Dirk Schrijvers; Jan Van den Brande; P Van Schil; Jan B Vermorken
Thoracic wall prosthesis prevents deep invasion by non-small-cell lung cancer.
American journal of clinical oncology 2000;23(1):32-3.
2000: Jan B Vermorken
Optimal treatment for ovarian cancer: taxoids and beyond.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():131-9.
2000: J Damen; Dirk Schrijvers; Jan Van den Brande; J Pelgrims; Jan B Vermorken
Intraperitoneal treatment of peritoneo-venous shunt infection in a cancer patient.
Scandinavian journal of infectious diseases 2000;32(1):106.
2000: J Pelgrims; Filip De Vos; Jan Van den Brande; Dirk Schrijvers; A Prové; Jan B Vermorken
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
British journal of cancer 2000;82(2):291-4.
1999: Judith R Kroep; Godefridus J Peters; Catharina J A Van Moorsel; A Catik; Jan B Vermorken; HERBERT PINEDO; Cees J van Groeningen
Gemcitabine-cisplatin: a schedule finding study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(12):1503-10.
1999: Jan Van den Brande; Dirk Schrijvers; C Colpaert; Jan B Vermorken
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(11):1369-72.
1999: Sergio Pecorelli; HC Wagenaar; Ignace Vergote; Desmond Curran; L V Beex; E Wiltshaw; Jan B Vermorken
Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study.
European journal of cancer (Oxford, England : 1990) 1999;35(9):1331-7.
1999: J Welink; Epie Boven; Jan B Vermorken; Helen Gall; Wim J F van der Vijgh
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2349-58.
1999: Jan B Vermorken; W W ten Bokkel Huinink; A Kobierska; M E L van der Burg; M Forni; M J Piccart; E van der Putten
Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma.
Oncology 1999;57(1):10-6.
1999: VR Panday; Wim W ten Bokkel Huinink; Jan B Vermorken; Hilde Rosing; FJ Koopman; M Swart; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; André Bergman; CM Kuiper; Jan B Vermorken; Wim J F van der Vijgh; Godefridus J Peters
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
British journal of cancer 1999;80(7):981-90.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; Jan B Vermorken; Pieter E Postmus; Godefridus J Peters
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
European journal of cancer (Oxford, England : 1990) 1999;35(5):808-14.
1999: Catharina J A Van Moorsel; Judith R Kroep; HERBERT PINEDO; Gijsbert Veerman; Daphne Voorn; Pieter E Postmus; Jan B Vermorken; Cees J van Groeningen; Wim J F van der Vijgh; Godefridus J Peters
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):441-8.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; A Guechev; Kees Smid; Willem J P Loves; Jan B Vermorken; Pieter E Postmus; Godefridus J Peters
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Biochemical pharmacology 1999;57(4):407-15.
1999: Dirk Schrijvers; Martin Highley; E De Bruyn; AT van Oosterom; Jan B Vermorken
Role of red blood cells in pharmacokinetics of chemotherapeutic agents.
Anti-cancer drugs 1999;10(2):147-53.
1999: Jan B Vermorken; A M E Claessen; H van Tinteren; Helen Gall; R Ezinga; Sybren Meijer; Rik J Scheper; Chris J L M Meijer; Elisabeth Bloemena; J H Ransom; M G Hanna; HERBERT PINEDO
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
Lancet 1999;353(9150):345-50.
1999: Tjeerd J Postma; Klaas Hoekman; J M G H van Riel; Jan J Heimans; Jan B Vermorken
Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
Journal of neuro-oncology 1999;45(3):241-6.
1999: Jan B Vermorken; P G Harper; Marc Buyse
The role of anthracyclines in epithelial ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10 Suppl 1():43-50.
1999: R van Gijn; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; Jan B Vermorken; Olaf van Tellingen; Hilde Rosing; LJ van Warmerdam; Jos H Beijnen
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1998: D Schrijvers; Jan Van den Brande; Jan B Vermorken
Pulmonary embolism.
The New England journal of medicine 1998;339(21):1555; author reply 1557.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; RE Henrar; Jan B Vermorken; Esteban Cvitkovic; Auke Bult; Jos H Beijnen
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 1998;33(11):1134-40.
1998: Dirk Schrijvers; C Tai-Apin; M C De Smet; P Cornil; Jan B Vermorken; P Bruyneel
Determination of compatibility and stability of drugs used in palliative care.
Journal of clinical pharmacy and therapeutics 1998;23(4):311-4.
1998: Tjeerd J Postma; Jan J Heimans; Martin J Muller; Gert Ossenkoppele; Jan B Vermorken; Neil K Aaronson
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(7):739-44.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; L Cameron; RE Henrar; Jan B Vermorken; Auke Bult; Jos H Beijnen
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1998;710(1-2):183-9.
1998: D Schrijvers; Jan B Vermorken
Update on the taxoids and other new agents in head and neck cancer therapy.
Current opinion in oncology 1998;10(3):233-41.
1998: AE Korst; ML van der Sterre; Helen Gall; AM Fichtinger-Schepman; Jan B Vermorken; Wim J F van der Vijgh
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):331-6.
1998: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; Jan B Vermorken; Giuseppe Giaccone; Cindy Veenhof; J H M Schellens; Jos H Beijnen
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: Catharina J A Van Moorsel; Gijsbert Veerman; Jan B Vermorken; Daphne Voorn; Judith R Kroep; André Bergman; HERBERT PINEDO; Godefridus J Peters
Mechanisms of synergism between gemcitabine and cisplatin.
Advances in experimental medicine and biology 1998;431():581-5.
1997: R E van Rijswijk; Klaas Hoekman; C W Burger; René H M Verheijen; Jan B Vermorken
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1235-41.
1997: Giuseppe Giaccone; SC Linn; J Welink; G Catimel; H Stieltjes; Wim J F van der Vijgh; CM Eeltink; Jan B Vermorken; HERBERT PINEDO
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2005-15.
1997: WM Mulder; Peter L Stern; MJ Stukart; E de Windt; R M Butzelaar; Sybren Meijer; H J Adér; A M E Claessen; Jan B Vermorken; Chris J L M Meijer; John Wagstaff; Rik J Scheper; Elisabeth Bloemena
Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):1923-30.
1997: Aafke H Honkoop; ELSKEN VAN DER WALL; Nicole Feller; Gerrit J Schuurhuis; Wim J F van der Vijgh; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Klaas Hoekman; Jan B Vermorken; John Wagstaff; HERBERT PINEDO
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):957-62.
1997: AE Korst; CM Eeltink; Jan B Vermorken; Wim J F van der Vijgh
Pharmacokinetics of amifostine and its metabolites in patients.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1425-9.
1997: VR Panday; manon huizing; P H Willemse; A De Graeff; Wim W ten Bokkel Huinink; Jan B Vermorken; Jos H Beijnen
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Seminars in oncology 1997;24(4 Suppl 11):S11-34-S11-38.
1997: SC Linn; HERBERT PINEDO; J van Ark-Otte; P van der Valk; Klaas Hoekman; Aafke H Honkoop; Jan B Vermorken; Giuseppe Giaccone
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy.
International journal of cancer. Journal international du cancer 1997;71(5):787-95.
1997: AE Korst; Jan B Vermorken; Wim J F van der Vijgh
High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(1):167-74.
1997: AE Korst; ML van der Sterre; CM Eeltink; AM Fichtinger-Schepman; Jan B Vermorken; Wim J F van der Vijgh
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):697-703.
1997: Catharina J A Van Moorsel; Gijsbert Veerman; André Bergman; A Guechev; Jan B Vermorken; Pieter E Postmus; Godefridus J Peters
Combination chemotherapy studies with gemcitabine.
Seminars in oncology 1997;24(2 Suppl 7):S7-17-S7-23.
1997: Jan B Vermorken; Jean-Paul Guastalla; S R Hatty; D E Seitz; B Tanis; C McDaniels; MD Clavel
Phase I study of gemcitabine using a once every 2 weeks schedule.
British journal of cancer 1997;76(11):1489-93.
1997: manon huizing; G Giaccone; LJ van Warmerdam; Hilde Rosing; P J M Bakker; Jan B Vermorken; P E Postmus; nico van zandwijk; M G Koolen; Wim W ten Bokkel Huinink; W J van der Vijgh; F J Bierhorst; A Lai; Otilia Dalesio; HERBERT PINEDO; Cindy Veenhof; Jos H Beijnen
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):317-29.
1996: Jaap Verweij; P H M De Mulder; A de Graeff; Jan B Vermorken; J Wildiers; J Kerger; Jan H Schornagel; F Cognetti; A Kirkpatrick; TM Sahmoud; J L Lefebvre
Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):867-9.
1996: Aafke H Honkoop; Klaas Hoekman; John Wagstaff; Cees J van Groeningen; Jan B Vermorken; Epie Boven; HERBERT PINEDO
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
British journal of cancer 1996;74(7):1132-6.
1996: Silvia von Mensdorff-Pouilly; M M Gourevitch; Peter Kenemans; AA Verstraeten; Sergey V Litvinov; Gerard J van Kamp; Sybren Meijer; Jan B Vermorken; JH Hilgers
Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1325-31.
1996: V W van Haperen; Gijsbert Veerman; Jan B Vermorken; HERBERT PINEDO; G Peters
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
Biochemical pharmacology 1996;51(7):911-8.
1996: K Hoekman; G Tognon; Elle K J Risse; C A Bloemsma; Jan B Vermorken
Well-differentiated papillary mesothelioma of the peritoneum: a separate entity.
European journal of cancer (Oxford, England : 1990) 1996;32A(2):255-8.
1996: Aafke H Honkoop; Klaas Hoekman; John Wagstaff; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Jan B Vermorken; HERBERT PINEDO
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):35-9.
1996: AE Korst; Helen Gall; Jan B Vermorken; Wim J F van der Vijgh
Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Cancer chemotherapy and pharmacology 1996;39(1-2):162-6.
1996: Gijsbert Veerman; Veronique Ruiz van Haperen; Jan B Vermorken; Paul Noordhuis; Boudewijn J M Braakhuis; HERBERT PINEDO; Godefridus J Peters
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Cancer chemotherapy and pharmacology 1996;38(4):335-42.
1995: R van Gijn; E Havik; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jos H Beijnen
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: manon huizing; Jan B Vermorken; Hilde Rosing; Wim W ten Bokkel Huinink; IA Mandjes; HERBERT PINEDO; Jos H Beijnen
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):699-704.
1995: Jan B Vermorken; K Hoekman
Chemotherapy for gynecologic malignancies.
Current opinion in oncology 1995;7(5):457-65.
1995: Giuseppe Giaccone; manon huizing; P E Postmus; Wim W ten Bokkel Huinink; M Koolen; nico van zandwijk; Jan B Vermorken; Jos H Beijnen; Otilia Dalesio; HERBERT PINEDO
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):78-82.
1995: Jan B Vermorken; Wim W ten Bokkel Huinink; I A Mandjes; Tjeerd J Postma; manon huizing; J J Heimans; Jos H Beijnen; F Bierhorst; B Winograd; HERBERT PINEDO
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Seminars in oncology 1995;22(4 Suppl 8):16-22.
1995: Jan H Schornagel; Jaap Verweij; P H M De Mulder; F Cognetti; Jan B Vermorken; P Cappelaere; J P Armand; J Wildiers; A de Graeff; M Clavel
Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1649-55.
1995: R van Gijn; Olaf van Tellingen; J J de Clippeleir; Michel J X Hillebrand; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; S Schwertz; P Graf; Jos H Beijnen
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: Tjeerd J Postma; Jan B Vermorken; A J Liefting; HERBERT PINEDO; Jan J Heimans
Paclitaxel-induced neuropathy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(5):489-94.
1995: K Hoekman; R V Huijskes; Curt W Burger; R H Verheijen; HERBERT PINEDO; Jan B Vermorken
[Favorable results of paclitaxel (Taxol) in patients with ovary carcinoma pretreated with platinum].
Nederlands tijdschrift voor geneeskunde 1995;139(6):272-8.
1995: Jan B Vermorken; A Kobierska; M E L van der Burg; B Chevallier; FLAVIA ZANABONI; Wim W ten Bokkel Huinink; M Forni; A Pawinski; E van der Putten; Giorgio Bolis
High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.
European journal of gynaecological oncology 1995;16(6):433-8.
1995: H H Boer; C M Moorer-van Delft; L J Müller; B Kiburg; Jan B Vermorken; Jan J Heimans
Ultrastructural neuropathologic effects of Taxol on neurons of the freshwater snail Lymnaea stagnalis.
Journal of neuro-oncology 1995;25(1):49-57.
1995: manon huizing; V H Misser; R C Pieters; Wim W ten Bokkel Huinink; Cindy Veenhof; Jan B Vermorken; HERBERT PINEDO; J H Beijnen
Taxanes: a new class of antitumor agents.
Cancer investigation 1995;13(4):381-404.
1995: N van der Vange; S Greggi; C W Burger; P Kenemans; Jan B Vermorken
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Acta oncologica (Stockholm, Sweden) 1995;34(6):813-20.
1994: Jan J Heimans; Jan B Vermorken; JG Wolbers; C M Eeltink; O W M Meijer; Martin J B Taphoorn; J H Beijnen
Paclitaxel (Taxol) concentrations in brain tumor tissue.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(10):951-3.
1994: Veronique Ruiz van Haperen; Gijsbert Veerman; Epie Boven; Paul Noordhuis; Jan B Vermorken; Godefridus J Peters
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Biochemical pharmacology 1994;48(7):1327-39.
1994: Jos H Beijnen; manon huizing; Wim W ten Bokkel Huinink; Cindy Veenhof; Jan B Vermorken; Giuseppe Giaccone; HERBERT PINEDO
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Seminars in oncology 1994;21(5 Suppl 8):53-62.
1994: Giuseppe Giaccone; manon huizing; Wim W ten Bokkel Huinink; M Koolen; P Postmus; K van Kralingen; nico van zandwijk; Jan B Vermorken; Jos H Beijnen; Otilia Dalesio
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Seminars in oncology 1994;21(5 Suppl 8):34-8.
1994: Veronique Ruiz van Haperen; Gijsbert Veerman; S Eriksson; Epie Boven; A P Stegmann; M Hermsen; Jan B Vermorken; HERBERT PINEDO; Godefridus J Peters
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Cancer research 1994;54(15):4138-43.
1994: M Clavel; Jan B Vermorken; F Cognetti; P Cappelaere; P H M De Mulder; Jan H Schornagel; Elias Tueni; Jaap Verweij; J Wildiers; M Clerico
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(6):521-6.
1994: K Hoekman; John Wagstaff; Jan B Vermorken; S Meijer; O W Meijer; HERBERT PINEDO
[Primary high-dose chemotherapy with hematopoietic growth factors followed by surgery and radiotherapy in stage III breast carcinoma; a Phase II study in 15 patients].
Nederlands tijdschrift voor geneeskunde 1994;138(21):1069-73.
1994: Klaas Hoekman; Jaap van Doorn; T Gloudemans; O S Hoekstra; J A Maassen; Jan B Vermorken; John Wagstaff; HERBERT PINEDO
Tumour-induced hypoglycaemia: a case report.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):277-81.
1994: Jan B Vermorken; Giorgio Bolis; R E van Rijswijk; A Kobierska; B Chevallier; M E L van der Burg; FLAVIA ZANABONI; M A Lentz; Curt W Burger; P Kenemans
High-dose intensity regimens with epirubicin in ovarian cancer.
Seminars in oncology 1994;21(1 Suppl 1):17-22.
1994: P H M De Mulder; P Cappelaere; F Cognetti; Jaap Verweij; Jan H Schornagel; Jan B Vermorken; A Kirkpatrick; J L Lefebvre
A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.
Cancer chemotherapy and pharmacology 1994;33(5):438-40.
1994: Jan B Vermorken
Consolidation therapy in patients with advanced ovarian cancer.
European journal of gynaecological oncology 1994;15(1):7-13.
1994: J P Guastalla; Jan B Vermorken; J A Wils; M George; V Scotto; M Nooij; W W ten Bokkel Huinnink; O Dalesio; J Renard
Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group.
European journal of cancer (Oxford, England : 1990) 1994;30A(1):45-9.
1994: Cindy Veenhof; M E L van der Burg; M Nooy; J G Aalders; S Pecorelli; C F Oliveira; N Rotmensz; Jan B Vermorken
Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma.
European journal of cancer (Oxford, England : 1990) 1994;30A(5):697-8.
1994: S Tumolo; B R Rao; M E L van der Burg; J P Guastalla; J Renard; Jan B Vermorken
Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study.
European journal of cancer (Oxford, England : 1990) 1994;30A(7):911-4.
1993: Jan B Vermorken; Jaap Verweij; P H M De Mulder; F Cognetti; M Clavel; S Rodenhuis; A Kirkpatrick; Gordon B Snow
Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):785-8.
1993: Veronique Ruiz van Haperen; Gijsbert Veerman; Jan B Vermorken; Godefridus J Peters
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
Biochemical pharmacology 1993;46(4):762-6.
1993: R C Pieters; Jan B Vermorken; H E Gall; J J Nauta; A C van Loenen; Cees J van Groeningen; R E van Rijswijk; J H Brenninkmeijer; HERBERT PINEDO
A double-blind randomized crossover study to compare the antiemetic efficacy of 250 mg with 500 mg methylprednisolone succinate (Solu-Medrol) as a single intravenous dose in patients treated with noncisplatin chemotherapy.
Oncology 1993;50(4):316-22.
1993: C A Yedema; Peter Kenemans; F Voorhorst; GG Bon; C Schijf; L Beex; AA Verstraeten; JH Hilgers; Jan B Vermorken
CA 125 half-life in ovarian cancer: a multivariate survival analysis.
British journal of cancer 1993;67(6):1361-7.
1993: R van Gijn; Hilde Rosing; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jan B Vermorken; A J Liefting; R Bruno; HERBERT PINEDO; Jos H Beijnen
Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;614(2):299-306.
1993: Jan B Vermorken; S Gundersen; M Clavel; John F Smyth; P Dodion; J Renard; Stanley B Kaye
Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(4):303-6.
1993: C D Richters; Curt W Burger; A A van de Loosdrecht; R E van Rijswijk; W Calame; O P Bleker; Jan B Vermorken; Peter Kenemans; Robert H J Beelen
The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment.
Cancer letters 1993;68(1):25-31.
1993: Jan B Vermorken; Wim W ten Bokkel Huinink; E A Eisenhauer; G Favalli; D Belpomme; P F Conte; S B Kaye
Advanced ovarian cancer. Carboplatin versus cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4 Suppl 4():41-8.
1993: Veronique Ruiz van Haperen; Gijsbert Veerman; Boudewijn J M Braakhuis; Jan B Vermorken; Epie Boven; A Leyva; Godefridus J Peters
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2132-7.
1992: J de Jong; G J Geijssen; C N Munniksma; Jan B Vermorken; Wim J F van der Vijgh
Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1897-906.
1992: Jan B Vermorken
High-dose intensity regimens with epirubicin in ovarian cancer.
Pathologie-biologie 1992;39(9):833.
1992: J de Jong; Jan B Vermorken; W J van der Vijgh
Analysis and pharmacokinetics of a new prodrug N-l-leucyldoxorubicin and its metabolites in plasma using HPLC with fluorescence detection.
Journal of pharmaceutical and biomedical analysis 1992;10(4):309-14.
1992: Jan H Schornagel; Jaap Verweij; P H M De Mulder; F Cognetti; Jan B Vermorken; P Cappelaere; J P Armand; J Wildiers; M Clavel; A Kirkpatrick
A phase II trial of 10-ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck. The EORTC Head and Neck Cancer Cooperative Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):223-6.
1992: L J Müller; C M Moorer-van Delft; E W Roubos; Jan B Vermorken; H H Boer
Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis.
Cancer research 1992;52(4):963-73.
1992: B C Tanis; Jan B Vermorken; Wim W ten Bokkel Huinink; AT van Oosterom; T A Splinter; K J Vendrik; D T Sleijfer; M E L van der Burg; E van der Putten; HERBERT PINEDO
Multicenter phase II study of spiroplatin.
Oncology 1992;49(2):99-103.
1992: HW Nijman; Curt W Burger; J P Baak; R Schats; Jan B Vermorken; Peter Kenemans
Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases.
European journal of cancer (Oxford, England : 1990) 1992;28A(12):1971-3.
1992: M E L van der Burg; S Monfardini; J P Guastalla; C de Oliveira; J Renard; Jan B Vermorken
Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.
European journal of cancer (Oxford, England : 1990) 1992;29A(1):147-8.
1991: K A Yedema; Peter Kenemans; T Wobbes; Gerard J van Kamp; H W de Bruijn; Chris M G Thomas; L F A G Massuger; C P T Schijf; GG Bon; Jan B Vermorken
Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
International journal of cancer. Journal international du cancer 1991;47(2):170-9.
1991: H M Oosterkamp; L T Vlasveld; Jantien Wanders; Jos H Beijnen; Olaf van Tellingen; A C Dubbelman; G P Simonetti; H R Franklin; Jan B Vermorken; Wim W ten Bokkel Huinink
Phase I study of vintriptol, a tryptophan ester of vinblastine.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1222-6.
1991: B C Tanis; Jan B Vermorken; Wim W ten Bokkel Huinink; I Klein; H Gall; A T van Oosterom; G Simonetti; J G McVie; Wim J F van der Vijgh; HERBERT PINEDO
Phase I study of spiroplatin.
European journal of cancer (Oxford, England : 1990) 1991;27(3):268-73.
1991: Veronique Ruiz van Haperen; Gijsbert Veerman; Paul Noordhuis; Jan B Vermorken; Godefridus J Peters
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Advances in experimental medicine and biology 1991;309A():57-60.
1991: Jan B Vermorken; S Tumolo; K J Roozendaal; J P Guastalla; T A Splinter; J Renard
5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix.
European journal of cancer (Oxford, England : 1990) 1991;27(2):216-7.
1990: P H M De Mulder; C Seynaeve; Jan B Vermorken; P A van Liessum; S Mols-Jevdevic; E L Allman; P Beranek; Jaap Verweij
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.
Annals of internal medicine 1990;113(11):834-40.
1990: Jaap Verweij; Jan H Schornagel; P H M De Mulder; S Henzen-Logmans; F Cognetti; M Clavel; Jan B Vermorken
Toxic dermatitis induced by 10-ethyl-10-deaza-aminopterin (10-EdAM), a novel antifolate.
Cancer 1990;66(9):1910-3.
1990: Gerrit J Schuurhuis; Henk J Broxterman; HERBERT PINEDO; T H van Heijningen; C K van Kalken; Jan B Vermorken; E C Spoelstra; Jan Lankelma
The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
British journal of cancer 1990;62(4):591-4.
1990: Jan B Vermorken
Chemotherapy and new treatments in squamous cell carcinoma of the head and neck.
Current opinion in oncology 1990;2(3):578-84.
1990: K R Durrant; C Mangioni; A J Lacave; M George; M E L van der Burg; D Guthrie; N Rotmenz; O Dalesio; Jan B Vermorken
Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG).
Gynecologic oncology 1990;37(3):359-62.
1990: Gilberto Schwartsmann; P Dodion; Jan B Vermorken; Wim W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; Wim J F van der Vijgh; M B van Hennik
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Cancer chemotherapy and pharmacology 1990;25(5):345-51.
1989: C J van Groeningen; H E Gall; K A Simons; A C van Loenen; M Tish Knobf; J Nauta; Jan B Vermorken; HERBERT PINEDO
Comparison of two different high doses of metoclopramide in the prevention of chemotherapy-induced emesis.
The Netherlands journal of medicine 1989;35(5-6):283-94.
1989: Gilberto Schwartsmann; Wim J F van der Vijgh; M B van Hennik; I Klein; Jan B Vermorken; P Dodion; Wim W ten Bokkel Huinink; G Joggi; H Gall; N Crespeigne
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
European journal of cancer & clinical oncology 1989;25(12):1675-81.
1989: John Wagstaff; Jan B Vermorken; G Schwartsmann; R J Scheper; C Erik Hack; J H Nuijens; A J Eerenberg-Belmer; HERBERT PINEDO
A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2.
Cancer treatment reviews 1989;16 Suppl A():105-9.
1989: Gilberto Schwartsmann; E Bork; Jan B Vermorken; C Nieboer; P Dodion; Wim W ten Bokkel Huinink; C A Seldenrijk; J P Armand; HERBERT PINEDO
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Cancer 1989;63(2):243-8.
1989: J P Neijt; M E van der Burg; J P Guastalla; M George; M Piccart; Jan B Vermorken; Flavio Carnino; N Rotmensz
Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.
Acta oncologica (Stockholm, Sweden) 1989;28(5):663-5.
1988: AT van Oosterom; M S Aapro; Flavio Carnino; M E L van der Burg; S Pecorelli; N Rotmensz; O Dalesio; Jan B Vermorken
Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group.
European journal of cancer & clinical oncology 1988;24(8):1379-80.
1988: Wim W ten Bokkel Huinink; M E L van der Burg; AT van Oosterom; J P Neijt; M George; J P Guastalla; Cindy Veenhof; N Rotmensz; Otilia Dalesio; Jan B Vermorken
Carboplatin in combination therapy for ovarian cancer.
Cancer treatment reviews 1988;15 Suppl B():9-15.
1988: Wim J F van der Vijgh; F Elferink; Jan B Vermorken; Wim W ten Bokkel Huinink; I Klein; H E Gall; G Simonetti; J G McVie; HERBERT PINEDO
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
European journal of cancer & clinical oncology 1988;24(4):621-7.
1988: Jan Lankelma; M Stuurman; J van Hoogenhuijze; A van Bochove; Jan B Vermorken; J Verweij; HERBERT PINEDO
The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration.
European journal of cancer & clinical oncology 1988;24(2):175-80.
1987: F Elferink; Wim J F van der Vijgh; I Klein; Jan B Vermorken; H E Gall; HERBERT PINEDO
Pharmacokinetics of carboplatin after i.v. administration.
Cancer treatment reports 1987;71(12):1231-7.
1987: M B van Hennik; Wim J F van der Vijgh; I Klein; F Elferink; Jan B Vermorken; B Winograd; HERBERT PINEDO
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
Cancer research 1987;47(23):6297-301.
1987: F Elferink; Wim J F van der Vijgh; Wim W ten Bokkel Huinink; Jan B Vermorken; I Klein; B Winograd; M Tish Knobf; G Simonetti; H E Gall; J G McVie
Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
British journal of cancer 1987;56(4):479-83.
1987: M E L van der Burg; Wim W ten Bokkel Huinink; R Vriesendorp; AT van Oosterom; J P Neijt; Jan B Vermorken; Wim L J van Putten; A Kooiman
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
European journal of cancer & clinical oncology 1987;23(7):997-8.
1987: M George; V Scotto; Flavio Carnino; P Dodion; Wim W ten Bokkel Huinink; N Rotmensz; Jan B Vermorken
Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.
European journal of cancer & clinical oncology 1987;23(6):867-9.
1986: F Cognetti; M Clerico; Jan B Vermorken; M Van Rymenant; A Rossi; A Kirkpatrick; O Dalesic; M Clavel
Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.
European journal of cancer & clinical oncology 1986;22(7):891-2.
1986: B Winograd; Jan B Vermorken; Wim W ten Bokkel Huinink; G Simonetti; H E Gall; M Tish Knobf; Wim J F van der Vijgh; J G McVie; HERBERT PINEDO
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Cancer research 1986;46(4 Pt 2):2148-51.
1985: J V Hamerlynck; A P Maskens; C Mangioni; M E L van der Burg; J A Wils; Jan B Vermorken; N Rotmensz
Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
Gynecologic oncology 1985;22(3):313-6.
1985: Jan B Vermorken; J P Armand; A J Lacave; M George; C F de Oliveira; F Cheix; A P Maskens; N Rotmensz
Phase II trial of bleomycin in patients with advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.
European journal of cancer & clinical oncology 1985;21(6):671-3.